Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 9238080 Bi-specific fusion proteins

Patent 9238080 was granted and assigned to Merrimack Pharmaceuticals on January, 2016 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Current Assignee

Merrimack Pharmaceuticals

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Date of Patent

January 19, 2016

Patent Application Number

13068808

Date Filed

May 20, 2011

Patent Citations Received

US Patent 11673970 Bi-specific fusion proteins

0

US Patent 12122819 Method of treating skin tissue damage by topically administering a bi-specific protein comprising a human insulin-like growth factor variant and a human annexin A5 variant

0

US Patent 12071482 Compositions and methods related to engineered Fc constructs

0

US Patent 11879002 Bi-specific therapeutic proteins, in vivo methods of use thereof and encoding nucleic acids thereof

0

Patent Primary Examiner

Patent abstract

Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 9238080 Bi-specific fusion proteins

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool